Migdal Insurance & Financial Holdings Ltd. Adverum Biotechnologies, Inc. Transaction History

Migdal Insurance & Financial Holdings Ltd.

$6.18 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$3.36 - $10.56 $159,784 - $502,180	-47,555 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$9.26 - $14.36 $273,271 - $423,777	29,511 Added 163.55%	47,555 $469,000
Q4 2020 Feb 08, 2021	BUY	$9.84 - $14.26 $177,552 - $257,307	18,044 New	18,044 $196,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.16 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$67,039
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$4,910
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $424M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.

Account